We have studied two well-known biological targets: the mutant tyrosine kinase T315I BCR-ABL inhibition, which is the main bioreceptor target for treating Chronic Myeloid Leukemia (CML) [20], and the human acetylcholinesterase (hAChE) inhibition, currently one of the main approaches to treating deleterious cognitive side effects of Alzheimer’s disease [21]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.